{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:10:12Z","timestamp":1756401012835,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,28]]},"DOI":"10.7759\/cureus.91185","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:29:38Z","timestamp":1756398578000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Anti-tumor Necrosis Factor (Anti-TNF) Therapy on Cardiovascular Risk in Patients With Ankylosing Spondylitis"],"prefix":"10.7759","author":[{"given":"Ahsan","family":"Amer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzana","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahsaan","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v16i3.9440","article-title":"Ankylosing spondylitis","volume":"16","author":"Ebrahimiadib N","year":"2021","unstructured":"Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani FG. Ankylosing spondylitis. J Ophthalmic Vis Res. 2021, 16:462-9. 10.18502\/jovr.v16i3.9440","journal-title":"J Ophthalmic Vis Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu W","year":"2019","unstructured":"Zhu W, He X, Cheng K, et al.. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019, 7:22. 10.1038\/s41413-019-0057-8","journal-title":"Bone Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2011.06.006","article-title":"Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications","volume":"22","author":"El Maghraoui A","year":"2011","unstructured":"El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011, 22:554-60. 10.1016\/j.ejim.2011.06.006","journal-title":"Eur J Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1704727","article-title":"Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review","volume":"20","author":"Atzeni F","year":"2020","unstructured":"Atzeni F, Nucera V, Galloway J, Zolt\u00e1n S, Nurmohamed M. Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. Expert Opin Biol Ther. 2020, 20:517-24. 10.1080\/14712598.2020.1704727","journal-title":"Expert Opin Biol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213448","article-title":"Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders","volume":"14","author":"Gonzalez Caldito N","year":"2023","unstructured":"Gonzalez Caldito N. Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders. Front Immunol. 2023, 14:1213448. 10.3389\/fimmu.2023.1213448","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1042\/CS20080196","article-title":"Role of TNF-alpha in vascular dysfunction","volume":"116","author":"Zhang H","year":"2009","unstructured":"Zhang H, Park Y, Wu J, et al.. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 2009, 116:219-30. 10.1042\/CS20080196","journal-title":"Clin Sci (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17938","article-title":"Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis","volume":"13","author":"Hussain A","year":"2021","unstructured":"Hussain A, Tarahomi T, Singh L, Bollampally M, Heydari-Kamjani M, Kesselman MM. Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis. Cureus. 2021, 13:e17938. 10.7759\/cureus.17938","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/IJICMR.S64894","article-title":"TNF-\u03b1 in the cardiovascular system: from physiology to therapy","volume":"9","author":"Urschel K","year":"2015","unstructured":"Urschel K, Cicha I. TNF-\u03b1 in the cardiovascular system: from physiology to therapy. Int J Interferon Cytokine Mediat Res. 2015, 9:25. 10.2147\/IJICMR.S64894","journal-title":"Int J Interferon Cytokine Mediat Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.7.1121","article-title":"Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs","volume":"9","author":"Avouac J","year":"2008","unstructured":"Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother. 2008, 9:1121-8. 10.1517\/14656566.9.7.1121","journal-title":"Expert Opin Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150389","article-title":"Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study","volume":"42","author":"Heinonen AV","year":"2015","unstructured":"Heinonen AV, Aaltonen KJ, Joensuu JT, et al.. Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol. 2015, 42:2339-46. 10.3899\/jrheum.150389","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3928\/00904481-20140924-10","article-title":"Erythrocyte sedimentation rate and C-reactive protein: how best to use them in clinical practice","volume":"43","author":"Litao MK","year":"2014","unstructured":"Litao MK, Kamat D. Erythrocyte sedimentation rate and C-reactive protein: how best to use them in clinical practice. Pediatr Ann. 2014, 43:417-20. 10.3928\/00904481-20140924-10","journal-title":"Pediatr Ann"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032775","article-title":"Inflammatory bowel disease and associated cardiovascular disease outcomes: a systematic review","volume":"102","author":"Jaiswal V","year":"2023","unstructured":"Jaiswal V, Batra N, Dagar M, et al.. Inflammatory bowel disease and associated cardiovascular disease outcomes: a systematic review. Medicine (Baltimore). 2023, 102:e32775. 10.1097\/MD.0000000000032775","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S464471","article-title":"Cardiovascular considerations and implications for treatment in psoriasis: an updated review","volume":"20","author":"Mehta H","year":"2024","unstructured":"Mehta H, Narang T, Dogra S, Handa S, Hatwal J, Batta A. Cardiovascular considerations and implications for treatment in psoriasis: an updated review. Vasc Health Risk Manag. 2024, 20:215-29. 10.2147\/VHRM.S464471","journal-title":"Vasc Health Risk Manag"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v15.i1.97458","article-title":"Endothelial dysfunction in the kidney transplant population: current evidence and management strategies","volume":"15","author":"Prabhahar A","year":"2025","unstructured":"Prabhahar A, Batta A, Hatwal J, Kumar V, Ramachandran R, Batta A. Endothelial dysfunction in the kidney transplant population: current evidence and management strategies. World J Transplant. 2025, 15:97458. 10.5500\/wjt.v15.i1.97458","journal-title":"World J Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4274\/raed.galenos.2022.25744","article-title":"Cardiovascular risk assessment after anti-TNF treatment in patients with rheumatoid arthritis and ankylosing spondylitis with strain echocardiography","volume":"14","author":"Y\u00f6nak AK","year":"2022","unstructured":"Y\u00f6nak AK, Dayan A, \u00d6zen G, S\u00fcnb\u00fcl M, Atag\u00fcnd\u00fcz MP, \u0130nan\u00e7 N. Cardiovascular risk assessment after anti-TNF treatment in patients with rheumatoid arthritis and ankylosing spondylitis with strain echocardiography. J Turk Soc Rheumatol. 2022, 14:117-23. 10.4274\/raed.galenos.2022.25744","journal-title":"J Turk Soc Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3623-8","article-title":"Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNF\u03b1 therapy: association with predictors of cardiovascular risk","volume":"36","author":"Maia DG","year":"2017","unstructured":"Maia DG, Augusto KL, Bezerra MC, Rodrigues CE. Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNF\u03b1 therapy: association with predictors of cardiovascular risk. Clin Rheumatol. 2017, 36:2371-6. 10.1007\/s10067-017-3623-8","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.02.014","article-title":"Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study","volume":"77","author":"Saougou I","year":"2010","unstructured":"Saougou I, Markatseli TE, Voulgari PV, Drosos AA. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine. 2010, 77:325-9. 10.1016\/j.jbspin.2010.02.014","journal-title":"Joint Bone Spine"},{"key":"ref18","article-title":"Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. The","volume":"33","author":"Spanakis E","year":"2006","unstructured":"Spanakis E, Sidiropoulos P, Papadakis J, et al.. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. The. J Rheumatol. 2006, 33:2440-6.","journal-title":"J Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.36660\/abc.202190703","article-title":"Effects of anti-TNF alpha therapy on blood pressure in resistant hypertensive subjects: a randomized, double-blind, placebo-controlled pilot study","volume":"116","author":"Faria AP","year":"2021","unstructured":"Faria AP, Ritter AM, Santa-Catharina A, et al.. Effects of anti-TNF alpha therapy on blood pressure in resistant hypertensive subjects: a randomized, double-blind, placebo-controlled pilot study. Arq Bras Cardiol. 2021, 116:443-51. 10.36660\/abc.202190703","journal-title":"Arq Bras Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04497-0","article-title":"Effects of 1-year anti-TNF-\u03b1 therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis","volume":"40","author":"V\u00e9gh E","year":"2020","unstructured":"V\u00e9gh E, Kerekes G, Pusztai A, et al.. Effects of 1-year anti-TNF-\u03b1 therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. Rheumatol Int. 2020, 40:427-36. 10.1007\/s00296-019-04497-0","journal-title":"Rheumatol Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2004.07.010","article-title":"Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis","volume":"34","author":"Peters MJ","year":"2004","unstructured":"Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004, 34:585-92. 10.1016\/j.semarthrit.2004.07.010","journal-title":"Semin Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v15.i11.553","article-title":"Cardiovascular implications of inflammatory bowel disease: an updated review","volume":"15","author":"Bhardwaj A","year":"2023","unstructured":"Bhardwaj A, Singh A, Midha V, Sood A, Wander GS, Mohan B, Batta A. Cardiovascular implications of inflammatory bowel disease: an updated review. World J Cardiol. 2023, 15:553-70. 10.4330\/wjc.v15.i11.553","journal-title":"World J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v17.i4.104717","article-title":"Emerging risk factors for heart failure in younger populations: a growing public health concern","volume":"17","author":"Parizad R","year":"2025","unstructured":"Parizad R, Batta A, Hatwal J, Taban-Sadeghi M, Mohan B. Emerging risk factors for heart failure in younger populations: a growing public health concern. World J Cardiol. 2025, 17:104717. 10.4330\/wjc.v17.i4.104717","journal-title":"World J Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393412-impact-of-anti-tumor-necrosis-factor-anti-tnf-therapy-on-cardiovascular-risk-in-patients-with-ankylosing-spondylitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:29:39Z","timestamp":1756398579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393412-impact-of-anti-tumor-necrosis-factor-anti-tnf-therapy-on-cardiovascular-risk-in-patients-with-ankylosing-spondylitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.91185","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}